These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

212 related articles for article (PubMed ID: 20957673)

  • 1. A multiplex model of combining gene-based, protein-based, and metabolite-based with positive and negative markers in urine for the early diagnosis of prostate cancer.
    Cao DL; Ye DW; Zhang HL; Zhu Y; Wang YX; Yao XD
    Prostate; 2011 May; 71(7):700-10. PubMed ID: 20957673
    [TBL] [Abstract][Full Text] [Related]  

  • 2. PSGR and PCA3 as biomarkers for the detection of prostate cancer in urine.
    Rigau M; Morote J; Mir MC; Ballesteros C; Ortega I; Sanchez A; Colás E; Garcia M; Ruiz A; Abal M; Planas J; Reventós J; Doll A
    Prostate; 2010 Dec; 70(16):1760-7. PubMed ID: 20672322
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A three-gene panel on urine increases PSA specificity in the detection of prostate cancer.
    Rigau M; Ortega I; Mir MC; Ballesteros C; Garcia M; Llauradó M; Colás E; Pedrola N; Montes M; Sequeiros T; Ertekin T; Majem B; Planas J; Ruiz A; Abal M; Sánchez A; Morote J; Reventós J; Doll A
    Prostate; 2011 Dec; 71(16):1736-45. PubMed ID: 21520154
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efforts to resolve the contradictions in early diagnosis of prostate cancer: a comparison of different algorithms of sarcosine in urine.
    Cao DL; Ye DW; Zhu Y; Zhang HL; Wang YX; Yao XD
    Prostate Cancer Prostatic Dis; 2011 Jun; 14(2):166-72. PubMed ID: 21321584
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Detection of TMPRSS2-ERG fusion transcripts and prostate cancer antigen 3 in urinary sediments may improve diagnosis of prostate cancer.
    Hessels D; Smit FP; Verhaegh GW; Witjes JA; Cornel EB; Schalken JA
    Clin Cancer Res; 2007 Sep; 13(17):5103-8. PubMed ID: 17785564
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Quadriplex model enhances urine-based detection of prostate cancer.
    Jamaspishvili T; Kral M; Khomeriki I; Vyhnankova V; Mgebrishvili G; Student V; Kolar Z; Bouchal J
    Prostate Cancer Prostatic Dis; 2011 Dec; 14(4):354-60. PubMed ID: 21788966
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Urine TMPRSS2:ERG Plus PCA3 for Individualized Prostate Cancer Risk Assessment.
    Tomlins SA; Day JR; Lonigro RJ; Hovelson DH; Siddiqui J; Kunju LP; Dunn RL; Meyer S; Hodge P; Groskopf J; Wei JT; Chinnaiyan AM
    Eur Urol; 2016 Jul; 70(1):45-53. PubMed ID: 25985884
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Rational basis for the combination of PCA3 and TMPRSS2:ERG gene fusion for prostate cancer diagnosis.
    Robert G; Jannink S; Smit F; Aalders T; Hessels D; Cremers R; Mulders PF; Schalken JA
    Prostate; 2013 Jan; 73(2):113-20. PubMed ID: 22674214
    [TBL] [Abstract][Full Text] [Related]  

  • 9. PCA3 sensitivity and specificity for prostate cancer detection in patients with abnormal PSA and/or suspicious digital rectal examination. First Latin American experience.
    Ramos CG; Valdevenito R; Vergara I; Anabalon P; Sanchez C; Fulla J
    Urol Oncol; 2013 Nov; 31(8):1522-6. PubMed ID: 22687565
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Contemporary role of prostate cancer antigen 3 in the management of prostate cancer.
    Auprich M; Bjartell A; Chun FK; de la Taille A; Freedland SJ; Haese A; Schalken J; Stenzl A; Tombal B; van der Poel H
    Eur Urol; 2011 Nov; 60(5):1045-54. PubMed ID: 21871709
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Progensa™ PCA3 test for prostate cancer.
    Durand X; Moutereau S; Xylinas E; de la Taille A
    Expert Rev Mol Diagn; 2011 Mar; 11(2):137-44. PubMed ID: 21405964
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Molecular diagnosis of prostate cancer: PCA3 and TMPRSS2:ERG gene fusion.
    Salagierski M; Schalken JA
    J Urol; 2012 Mar; 187(3):795-801. PubMed ID: 22245323
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The time-resolved fluorescence-based PCA3 test on urinary sediments after digital rectal examination; a Dutch multicenter validation of the diagnostic performance.
    van Gils MP; Hessels D; van Hooij O; Jannink SA; Peelen WP; Hanssen SL; Witjes JA; Cornel EB; Karthaus HF; Smits GA; Dijkman GA; Mulders PF; Schalken JA
    Clin Cancer Res; 2007 Feb; 13(3):939-43. PubMed ID: 17289888
    [TBL] [Abstract][Full Text] [Related]  

  • 14. PCA3: a molecular urine assay for predicting prostate biopsy outcome.
    Deras IL; Aubin SM; Blase A; Day JR; Koo S; Partin AW; Ellis WJ; Marks LS; Fradet Y; Rittenhouse H; Groskopf J
    J Urol; 2008 Apr; 179(4):1587-92. PubMed ID: 18295257
    [TBL] [Abstract][Full Text] [Related]  

  • 15. PCA3 molecular urine assay for prostate cancer in men undergoing repeat biopsy.
    Marks LS; Fradet Y; Deras IL; Blase A; Mathis J; Aubin SM; Cancio AT; Desaulniers M; Ellis WJ; Rittenhouse H; Groskopf J
    Urology; 2007 Mar; 69(3):532-5. PubMed ID: 17382159
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Combining urinary detection of TMPRSS2:ERG and PCA3 with serum PSA to predict diagnosis of prostate cancer.
    Salami SS; Schmidt F; Laxman B; Regan MM; Rickman DS; Scherr D; Bueti G; Siddiqui J; Tomlins SA; Wei JT; Chinnaiyan AM; Rubin MA; Sanda MG
    Urol Oncol; 2013 Jul; 31(5):566-71. PubMed ID: 21600800
    [TBL] [Abstract][Full Text] [Related]  

  • 17. PCA3 molecular urine assay correlates with prostate cancer tumor volume: implication in selecting candidates for active surveillance.
    Nakanishi H; Groskopf J; Fritsche HA; Bhadkamkar V; Blase A; Kumar SV; Davis JW; Troncoso P; Rittenhouse H; Babaian RJ
    J Urol; 2008 May; 179(5):1804-9; discussion 1809-10. PubMed ID: 18353398
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Urine markers in monitoring for prostate cancer.
    Jamaspishvili T; Kral M; Khomeriki I; Student V; Kolar Z; Bouchal J
    Prostate Cancer Prostatic Dis; 2010 Mar; 13(1):12-9. PubMed ID: 19652665
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The role of the PCA3 assay in predicting prostate biopsy outcome in a South African setting.
    Adam A; Engelbrecht MJ; Bornman MS; Manda SO; Moshokoa E; Feilat RA
    BJU Int; 2011 Dec; 108(11):1728-33. PubMed ID: 21507188
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Annexin A3 in urine: a highly specific noninvasive marker for prostate cancer early detection.
    Schostak M; Schwall GP; Poznanović S; Groebe K; Müller M; Messinger D; Miller K; Krause H; Pelzer A; Horninger W; Klocker H; Hennenlotter J; Feyerabend S; Stenzl A; Schrattenholz A
    J Urol; 2009 Jan; 181(1):343-53. PubMed ID: 19012935
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.